Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIML-NK cell therapy
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CIML-NK cell therapy is an investigational adoptive cellular immunotherapy developed by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy consists of donor-derived natural killer (NK) cells that are activated ex vivo with a specific cytokine cocktail comprising interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18). This brief activation induces a "memory-like" phenotype, resulting in NK cells that exhibit enhanced proliferative capacity, increased production of interferon-gamma (IFN-γ), and more potent cytotoxicity against leukemic cells compared to conventional NK cells. In clinical protocols at MSKCC, these CIML-NK cells are administered to patients following lymphodepletion and are evaluated in combination with the PD-L1 inhibitor atezolizumab and systemic IL-2 support to enhance anti-leukemic activity and overcome immune suppression.
- Other names
- Cytokine-induced memory-like natural killer cellsCIML-NK cellsCytokine Induced Memory-Like Natural Killer Cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL-18R (Interleukin-18 receptor complex)IL2RB (IL-2 receptor beta chain)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on CIML-NK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIML-NK cell therapy.